Fungal diseases kill more than 1.5 million people per year, mostly in regions where
neglected populations live [1]. This alarming number of deaths is part of a highly complex …

The pharmaceutical industry had a glorious year in 2022, with a total of 37 new drugs
including 20 new chemical entities (NCEs) and 17 new biological entities (NBEs) approved …

Fungal infections of the central nervous system (FI-CNS) are a problematic and important
medical challenge considering that those most affected are immunocompromised …

Introduction Antifungal resistance (AFR) is a growing global public health concern. Little is
currently known about knowledge, attitudes and practices regarding AFR and antifungal …

The studies on metal complexes as potential antifungals are of growing interest because
they may be the answer to increasingly effective defense mechanisms. Herein we present …

Systemic fungal infections are a growing public health threat, and yet viable antifungal drug
targets are limited as fungi share a similar proteome with humans. However, features of RNA …

This study investigated the presence of 46 pharmaceuticals and personal care products
(PPCPs), including antibiotics, anti-inflammatory, antifungal, surfactant, antidepressants, and …

In the era of antiretroviral therapy, the prevalence of Cryptococcal infection among HIV
patients in developed countries has decreased considerably. However, C. neoformans …

The iron chelating orphan drug deferiprone (L1), discovered over 40 years ago, has been
used daily by patients across the world at high doses (75–100 mg/kg) for more than 30 years …

Background: Antimicrobial resistance (AMR) is a global public health problem that is fuelled
by the inappropriate prescribing of antibiotics, especially those from the 'watch'and …